Boston Scientific Corp. (BSX), the second-biggest maker of heart-rhythm devices, is on pace to increase annual sales for the first time since 2009, marking the end of a downturn that saw net losses in seven of the past eight years.
While the market for products such as defibrillators and drug-coated stents used to prop open clogged heart arteries are flat or shrinking, Boston Scientific’s sales rose 5.5 percent and 9.1 percent, respectively, the company reported. Seven of its eight product categories topped the market growth rate in the quarter, Chief Executive Officer Michael Mahoney said.
Help employers find you! Check out all the jobs and post your resume.
